1. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003;349(23):2241-2252.
2. J. Ferlay IS, M. Ervik, R. Dikshit, S. Eser, C. Mathers, M. Rebelo, D. M. Parkin, D. Forman, F.
Bray. GLOBOCAN 2012 v1.1, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11:
Lyon, France: International Agency for Research on Cancer; 2012 [Abrufbar unter:
http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx] (Zugriff am: 17.11.2016).
3. Arnold M, Soerjomataram I, Ferlay J, Forman D. Global incidence of oesophageal cancer by histological subtype in 2012. Gut. 2015;64(3):381-387.
4. Kamangar F, Dores GM, Anderson WF. Patterns of Cancer Incidence, Mortality, and Prevalence Across Five Continents: Defining Priorities to Reduce Cancer Disparities in Different Geographic Regions of the World. Journal of Clinical Oncology. 2006;24(14):2137-2150.
5. Howlader N NA, Krapcho M, Miller D, Bishop K, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA. SEER Cancer Statistics Review:
National Cancer Institute. Bethesda, MD; 1975-2013 [updated based on November 2015 SEER data submission, posted to the SEER web site, April 2016. Abrufbar unter:
http://seer.cancer.gov/csr/1975_2013/ (Zugriff am: 17.11.2016).
6. Thrift AP, El-Serag HB. Sex and Racial Disparity in Incidence of Esophageal Adenocarcinoma:
Observations and Explanations. Clin Gastroenterol Hepatol. 2016;14(3):330-332.
7. Cook MB, Kamangar F, Whiteman DC, Freedman ND, Gammon MD, Bernstein L, et al.
Cigarette smoking and adenocarcinomas of the esophagus and esophagogastric junction: a pooled analysis from the international BEACON consortium. J Natl Cancer Inst. 2010;102(17):1344-1353.
8. Prabhu A, Obi KO, Rubenstein JH. The synergistic effects of alcohol and tobacco consumption on the risk of esophageal squamous cell carcinoma: a meta-analysis. Am J Gastroenterol.
2014;109(6):822-827.
9. Pandeya N, Williams G, Green AC, Webb PM, Whiteman DC, Australian Cancer S. Alcohol consumption and the risks of adenocarcinoma and squamous cell carcinoma of the esophagus.
Gastroenterology. 2009;136(4):1215-1224, e1211-1212.
10. Cook MB, Corley DA, Murray LJ, Liao LM, Kamangar F, Ye W, et al. Gastroesophageal reflux in relation to adenocarcinomas of the esophagus: a pooled analysis from the Barrett's and Esophageal Adenocarcinoma Consortium (BEACON). PLoS One. 2014;9(7):e103508.
11. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999;340(11):825-831.
12. Hvid-Jensen F, Pedersen L, Drewes AM, Sorensen HT, Funch-Jensen P. Incidence of
adenocarcinoma among patients with Barrett's esophagus. N Engl J Med. 2011;365(15):1375-1383.
13. Steffen A, Huerta JM, Weiderpass E, Bueno-de-Mesquita HB, May AM, Siersema PD, et al.
General and abdominal obesity and risk of esophageal and gastric adenocarcinoma in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2015;137(3):646-657.
14. Hoyo C, Cook MB, Kamangar F, Freedman ND, Whiteman DC, Bernstein L, et al. Body mass index in relation to oesophageal and oesophagogastric junction adenocarcinomas: a pooled analysis from the International BEACON Consortium. Int J Epidemiol. 2012;41(6):1706-1718.
15. Piper W. Innere Medizin. 2., überarb. Aufl. ed. Berlin: Springer; 2013. Online-Ressource. p.
16. Vaughan TL, Davis S, Kristal A, Thomas DB. Obesity, alcohol, and tobacco as risk factors for cancers of the esophagus and gastric cardia: adenocarcinoma versus squamous cell carcinoma.
Cancer Epidemiol Biomarkers Prev. 1995;4(2):85-92.
17. Lahmann PH, Pandeya N, Webb PM, Green AC, Whiteman DC, Australian Cancer S. Body mass index, long-term weight change, and esophageal squamous cell carcinoma: is the inverse association modified by smoking status? Cancer. 2012;118(7):1901-1909.
18. Sadeghi S, Bain CJ, Pandeya N, Webb PM, Green AC, Whiteman DC, et al. Aspirin,
nonsteroidal anti-inflammatory drugs, and the risks of cancers of the esophagus. Cancer Epidemiol Biomarkers Prev. 2008;17(5):1169-1178.
67
19. Asamura H, Sobin LH, Wittekind C, Ohio Library and Information Network. TNM atlas : illustrated guide to the TNM classification of malignant tumors. Sixth edition ed2014. 1 online resource (xvii, 390 pages). p.
20. Siewert JR, Stein HJ. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg. 1998;85(11):1457-1459.
21. Edge SB BD, Compton CC, Fritz AG, Greene FL, Trotti A, editors. AJCC cancer staging manual (7th ed). New York, NY: Springer; 2010. p.
22. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Diagnostik und Therapie der Plattenepithelkarzinome und Adenokarzinome des Ösophagus, Langversion 1.0, 2015, AWMF Registernummer: 021/023OL, [Abrufbar unter:
http://leitlinienprogramm-onkologie.de/Leitlinien.7.0.html] (Zugriff am: 20.02.2017).
23. Behrens A, Labenz J, Schuler A, Schroder W, Runzi M, Steinmann RU, et al. [How safe is sedation in gastrointestinal endoscopy? A multicentre analysis of 388,404 endoscopies and analysis of data from prospective registries of complications managed by members of the Working Group of Leading Hospital Gastroenterologists (ALGK)]. Z Gastroenterol. 2013;51(5):432-436.
24. Kinkel K, Lu Y, Both M, Warren RS, Thoeni RF. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. Radiology. 2002;224(3):748-756.
25. Takizawa K, Matsuda T, Kozu T, Eguchi T, Kato H, Nakanishi Y, et al. Lymph node staging in esophageal squamous cell carcinoma: a comparative study of endoscopic ultrasonography versus computed tomography. J Gastroenterol Hepatol. 2009;24(10):1687-1691.
26. Lowe VJ, Booya F, Fletcher JG, Nathan M, Jensen E, Mullan B, et al. Comparison of positron emission tomography, computed tomography, and endoscopic ultrasound in the initial staging of patients with esophageal cancer. Mol Imaging Biol. 2005;7(6):422-430.
27. Thosani N, Singh H, Kapadia A, Ochi N, Lee JH, Ajani J, et al. Diagnostic accuracy of EUS in differentiating mucosal versus submucosal invasion of superficial esophageal cancers: a systematic review and meta-analysis. Gastrointest Endosc. 2012;75(2):242-253.
28. Wakamatsu T, Tsushima K, Yasuo M, Yamazaki Y, Yoshikawa S, Koide N, et al. Usefulness of preoperative endobronchial ultrasound for airway invasion around the trachea: esophageal cancer and thyroid cancer. Respiration. 2006;73(5):651-657.
29. Omloo JM, van Heijl M, Bergman JJ, Koolen MG, van Berge Henegouwen MI, van Lanschot JJ.
Value of bronchoscopy after EUS in the preoperative assessment of patients with esophageal cancer at or above the carina. J Gastrointest Surg. 2008;12(11):1874-1879.
30. Bunting DM, Lai WW, Berrisford RG, Wheatley TJ, Drake B, Sanders G. Positron emission tomography-computed tomography in oesophageal cancer staging: a tailored approach. World J Surg. 2015;39(4):1000-1007.
31. Bruzzi JF, Munden RF, Truong MT, Marom EM, Sabloff BS, Gladish GW, et al. PET/CT of esophageal cancer: its role in clinical management. Radiographics. 2007;27(6):1635-1652.
32. Berry MF. Esophageal cancer: staging system and guidelines for staging and treatment. J Thorac Dis. 2014;6 Suppl 3:S289-297.
33. Wilson M, Rosato EL, Chojnacki KA, Chervoneva I, Kairys JC, Cohn HE, et al. Prognostic
significance of lymph node metastases and ratio in esophageal cancer. J Surg Res. 2008;146(1):11-15.
34. Convie L, Thompson RJ, Kennedy R, Clements WD, Carey PD, Kennedy JA. The current role of staging laparoscopy in oesophagogastric cancer. Ann R Coll Surg Engl. 2015;97(2):146-150.
35. de Graaf GW, Ayantunde AA, Parsons SL, Duffy JP, Welch NT. The role of staging laparoscopy in oesophagogastric cancers. Eur J Surg Oncol. 2007;33(8):988-992.
36. Pech O, Bollschweiler E, Manner H, Leers J, Ell C, Holscher AH. Comparison between
endoscopic and surgical resection of mucosal esophageal adenocarcinoma in Barrett's esophagus at two high-volume centers. Ann Surg. 2011;254(1):67-72.
37. Prasad GA, Wu TT, Wigle DA, Buttar NS, Wongkeesong LM, Dunagan KT, et al. Endoscopic and surgical treatment of mucosal (T1a) esophageal adenocarcinoma in Barrett's esophagus.
Gastroenterology. 2009;137(3):815-823.
68
38. Pech O, Behrens A, May A, Nachbar L, Gossner L, Rabenstein T, et al. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett's oesophagus. Gut.
2008;57(9):1200-1206.
39. Manner H, May A, Pech O, Gossner L, Rabenstein T, Gunter E, et al. Early Barrett's carcinoma with "low-risk" submucosal invasion: long-term results of endoscopic resection with a curative intent.
Am J Gastroenterol. 2008;103(10):2589-2597.
40. Pech O, May A, Manner H, Behrens A, Pohl J, Weferling M, et al. Long-term efficacy and safety of endoscopic resection for patients with mucosal adenocarcinoma of the esophagus.
Gastroenterology. 2014;146(3):652-660 e651.
41. Ell C, May A, Gossner L, Pech O, Gunter E, Mayer G, et al. Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett's esophagus. Gastroenterology. 2000;118(4):670-677.
42. Ell C, May A, Pech O, Gossner L, Guenter E, Behrens A, et al. Curative endoscopic resection of early esophageal adenocarcinomas (Barrett's cancer). Gastrointest Endosc. 2007;65(1):3-10.
43. Alvarez Herrero L, Pouw RE, van Vilsteren FG, ten Kate FJ, Visser M, van Berge Henegouwen MI, et al. Risk of lymph node metastasis associated with deeper invasion by early adenocarcinoma of the esophagus and cardia: study based on endoscopic resection specimens. Endoscopy.
2010;42(12):1030-1036.
44. Fitzgerald RC, di Pietro M, Ragunath K, Ang Y, Kang JY, Watson P, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut.
2014;63(1):7-42.
45. Cummings LC, Kou TD, Schluchter MD, Chak A, Cooper GS. Outcomes after endoscopic versus surgical therapy for early esophageal cancers in an older population. Gastrointest Endosc.
2016;84(2):232-240 e231.
46. Erckenbrecht JF. Viszeralmedizin: interdisziplinäres Facharztwissen Gastroenterologie und Viszeralchirurgie. Berlin ; Heidelberg: Springer; 2015. XVI, 690 S. p.
47. Gnant M. Chirurgische Onkologie: Strategien und Standards für die Praxis. Wien u.a.:
Springer; 2008. XXIX, 516 S. p.
48. Ronellenfitsch U, Schwarzbach M, Hofheinz R, Kienle P, Kieser M, Slanger TE, et al.
Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus. Cochrane Database Syst Rev.
2013(5):CD008107.
49. Pasquali S, Yim G, Vohra RS, Mocellin S, Nyanhongo D, Marriott P, et al. Survival After Neoadjuvant and Adjuvant Treatments Compared to Surgery Alone for Resectable Esophageal Carcinoma: A Network Meta-analysis. Ann Surg. 2017;265(3):481-491.
50. Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;12(7):681-692.
51. Bedenne L, Michel P, Bouché O, Milan C, Mariette C, Conroy T, et al. Chemoradiation Followed by Surgery Compared With Chemoradiation Alone in Squamous Cancer of the Esophagus:
FFCD 9102. Journal of Clinical Oncology. 2007;25(10):1160-1168.
52. Jeene PM, Versteijne E, van Berge Henegouwen MI, Bergmann JJ, Geijsen ED, van Laarhoven HW, et al. Supraclavicular node disease is not an independent prognostic factor for survival of esophageal cancer patients treated with definitive chemoradiation. Acta Oncol. 2017;56(1):33-38.
53. Herskovic A, Martz K, Al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. New England Journal of Medicine. 1992;326(24):1593-1598.
54. Ariga H, Nemoto K, Miyazaki S, Yoshioka T, Ogawa Y, Sakayauchi T, et al. Prospective Comparison of Surgery Alone and Chemoradiotherapy With Selective Surgery in Resectable Squamous Cell Carcinoma of the Esophagus. International Journal of Radiation
Oncology*Biology*Physics. 2009;75(2):348-356.
69
55. Marks JL, Hofstetter W, Correa AM, Mehran RJ, Rice D, Roth J, et al. Salvage esophagectomy after failed definitive chemoradiation for esophageal adenocarcinoma. The Annals of thoracic surgery. 2012;94(4):1126-1133.
56. Network NCC. Esophageal and Esophagogastric Junction Cancers (Version I. 2017) 2017 [Abrufbar unter: https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf] (Zugriff am:
05.10.2017).
57. Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, et al. INT 0123 (Radiation Therapy Oncology Group 94-05) Phase III Trial of Combined-Modality Therapy for
Esophageal Cancer: High-Dose Versus Standard-Dose Radiation Therapy. Journal of Clinical Oncology.
2002;20(5):1167-1174.
58. Geh JI, Bond SJ, Bentzen SM, Glynne-Jones R. Systematic overview of preoperative (neoadjuvant) chemoradiotherapy trials in oesophageal cancer: Evidence of a radiation and chemotherapy dose response. Radiotherapy and Oncology.78(3):236-244.
59. Wannenmacher M. Strahlentherapie: mit 298 Tabellen. 2., überarb. Aufl. ed. Berlin u.a.:
Springer; 2013. XVIII,1087 S. p.
60. Roeder F, Nicolay NH, Nguyen T, Saleh-Ebrahimi L, Askoxylakis V, Bostel T, et al. Intensity modulated radiotherapy (IMRT) with concurrent chemotherapy as definitive treatment of locally advanced esophageal cancer. Radiat Oncol. 2014;9:191.
61. Lin SH, Wang L, Myles B, Thall PF, Hofstetter WL, Swisher SG, et al. Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs
intensity-modulated radiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2012;84(5):1078-1085.
62. Hsu F-M, Lee J-M, Huang P-M, Lin C-C, Hsu C-H, Tsai Y-C, et al. Retrospective Analysis of Outcome Differences in Preoperative Concurrent Chemoradiation With or Without Elective Nodal Irradiation for Esophageal Squamous Cell Carcinoma. International Journal of Radiation
Oncology*Biology*Physics. 2011;81(4):e593-e599.
63. Yamashita H, Takenaka R, Omori M, Imae T, Okuma K, Ohtomo K, et al. Involved-field radiotherapy (IFRT) versus elective nodal irradiation (ENI) in combination with concurrent
chemotherapy for 239 esophageal cancers: a single institutional retrospective study. Radiat Oncol.
2015;10:171.
64. Miller KR, Bozeman MC. Nutrition therapy issues in esophageal cancer. Curr Gastroenterol Rep. 2012;14(4):356-366.
65. Margolis M, Alexander P, Trachiotis GD, Gharagozloo F, Lipman T. Percutaneous endoscopic gastrostomy before multimodality therapy in patients with esophageal cancer. The Annals of Thoracic Surgery.76(5):1694-1698.
66. Siersema PD. Treatment options for esophageal strictures. Nat Clin Pract Gastroenterol Hepatol. 2008;5(3):142-152.
67. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet (London, England). 2010;376(9742):687-697.
68. Sabharwal T, Hamady MS, Chui S, Atkinson S, Mason R, Adam A. A randomised prospective comparison of the Flamingo Wallstent and Ultraflex stent for palliation of dysphagia associated with lower third oesophageal carcinoma. Gut. 2003;52(7):922-926.
69. Homs MY, Steyerberg EW, Eijkenboom WM, Tilanus HW, Stalpers LJ, Bartelsman JF, et al.
Single-dose brachytherapy versus metal stent placement for the palliation of dysphagia from oesophageal cancer: multicentre randomised trial. Lancet (London, England). 2004;364(9444):1497-1504.
70. Molena D, Stem M, Blackford AL, Lidor AO. Esophageal Cancer Treatment Is Underutilized Among Elderly Patients in the USA. J Gastrointest Surg. 2017;21(1):126-136.
71. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383.
70
72. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205-213.
73. NCI N, DHHS. NCI Common Terminology Criteria for Adverse Events (CTCAE). In: SERVICES USDOHAH, editor.: National Cancer Institute; 2010 [Available from:
http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf] (Zugriff am:
26.04.2016).
74. Meier ELKaP. Nonparametric Estimation from Incomplete Observations. Journal of the American Statistical Association. 1958;53:457-481.
75. Hulshof MC, van Laarhoven HW. Chemoradiotherapy in tumours of the oesophagus and gastro-oesophageal junction. Best Pract Res Clin Gastroenterol. 2016;30(4):551-563.
76. al-Sarraf M, Martz K, Herskovic A, Leichman L, Brindle JS, Vaitkevicius VK, et al. Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. J Clin Oncol. 1997;15(1):277-284.
77. van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074-2084.
78. Hutchins LF, Unger JM, Crowley JJ, Coltman CA, Jr., Albain KS. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999;341(27):2061-2067.
79. Scher KS, Hurria A. Under-representation of older adults in cancer registration trials: known problem, little progress. J Clin Oncol. 2012;30(17):2036-2038.
80. Smit JK, Muijs CT, Burgerhof JG, Paardekooper G, Timmer PR, Muller K, et al. Survival after definitive (chemo)radiotherapy in esophageal cancer patients: a population-based study in the north-East Netherlands. Ann Surg Oncol. 2013;20(6):1985-1992.
81. Tougeron D, Di Fiore F, Thureau S, Berbera N, Iwanicki-Caron I, Hamidou H, et al. Safety and outcome of definitive chemoradiotherapy in elderly patients with oesophageal cancer. Br J Cancer.
2008;99(10):1586-1592.
82. Mak RH, Mamon HJ, Ryan DP, Miyamoto DT, Ancukiewicz M, Kobayashi WK, et al. Toxicity and outcomes after chemoradiation for esophageal cancer in patients age 75 or older. Dis
Esophagus. 2010;23(4):316-323.
83. Takeuchi S, Ohtsu A, Doi T, Kojima T, Minashi K, Mera K, et al. A retrospective study of definitive chemoradiotherapy for elderly patients with esophageal cancer. Am J Clin Oncol.
2007;30(6):607-611.
84. Kawashima M, Kagami Y, Toita T, Uno T, Sugiyama M, Tamura Y, et al. Prospective trial of radiotherapy for patients 80 years of age or older with squamous cell carcinoma of the thoracic esophagus. Int J Radiat Oncol Biol Phys. 2006;64(4):1112-1121.
85. Kosugi S, Sasamoto R, Kanda T, Matsuki A, Hatakeyama K. Retrospective review of surgery and definitive chemoradiotherapy in patients with squamous cell carcinoma of the thoracic esophagus aged 75 years or older. Jpn J Clin Oncol. 2009;39(6):360-366.
86. Voncken FEM, van der Kaaij RT, Sikorska K, van Werkhoven E, van Dieren JM, Grootscholten C, et al. Advanced Age is Not a Contraindication for Treatment With Curative Intent in Esophageal Cancer. Am J Clin Oncol. 2017.
87. Nomura M, Shitara K, Kodaira T, Kondoh C, Takahari D, Ura T, et al. Recursive partitioning analysis for new classification of patients with esophageal cancer treated by chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2012;84(3):786-792.
88. Haefner MF, Lang K, Krug D, Koerber SA, Uhlmann L, Kieser M, et al. Prognostic factors, patterns of recurrence and toxicity for patients with esophageal cancer undergoing definitive radiotherapy or chemo-radiotherapy. Journal of Radiation Research. 2015;56(4):742-749.
89. Anderson SE, Minsky BD, Bains M, Hummer A, Kelsen D, Ilson DH. Combined modality chemoradiation in elderly oesophageal cancer patients. Br J Cancer. 2007;96(12):1823-1827.
90. Stahl M, Stuschke M, Lehmann N, Meyer H-J, Walz MK, Seeber S, et al. Chemoradiation With and Without Surgery in Patients With Locally Advanced Squamous Cell Carcinoma of the Esophagus.
Journal of Clinical Oncology. 2005;23(10):2310-2317.
71
91. Wang H, Ryu J, Gandara D, Bold RJ, Urayama S, Tanaka M, et al. A Phase II Study of Paclitaxel, Carboplatin, and Radiation with or without Surgery for Esophageal Cancer. Journal of Thoracic Oncology. 2007;2(2):153-157.
92. Honing J, Smit JK, Muijs CT, Burgerhof JG, de Groot JW, Paardekooper G, et al. A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients. Ann Oncol. 2014;25(3):638-643.
93. Xi M, Xu C, Liao Z, Hofstetter WL, Blum Murphy M, Maru DM, et al. The impact of histology on recurrence patterns in esophageal cancer treated with definitive chemoradiotherapy. Radiother Oncol. 2017;124(2):318-324.
94. Metzger J-C, Wollschläger D, Miederer M, Vaupel P, Moehler M, Schmidberger H, et al.
Inclusion of PET-CT into planning of primary or neoadjuvant chemoradiotherapy of esophageal cancer improves prognosis. Strahlentherapie und Onkologie. 2017;193(10):791-799.
95. Freilich J, Hoffe SE, Almhanna K, Dinwoodie W, Yue B, Fulp W, et al. Comparative outcomes for three-dimensional conformal versus intensity-modulated radiation therapy for esophageal cancer. Dis Esophagus. 2015;28(4):352-357.
72
7 Danksagung
Besonderen Dank möchte ich Herrn PD Dr. Roeder für die Überlassung des Themas und die exzellente Betreuung aussprechen. Darüber hinaus bedanke ich mich herzlich für die aufrichtige Unterstützung in beruflicher und persönlicher Hinsicht.
Ebenso möchte ich mich bei Frau Dr. Walter für die Betreuung und die geduldige Begleitung der Dissertation bedanken.
Des Weiteren bin ich auch den Mitarbeitern der Klinik für Strahlentherapie und Radioonkologie der Universität, insbesondere Frau Förster und Frau Sirges-Szasz, für die Unterstützung dankbar.
Herzlich bedanken möchte ich an dieser Stelle bei meiner Familie und meiner Freundin, die mich bei der Verwirklichung meines Studiums und des Promotionsvorhabens jederzeit unterstützt haben.